Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your experience. Save up to 40% More details

Pfizer to pay $11.6 billion for Biohaven to tap migraine market

Stock Markets May 10, 2022 02:57PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
2/2 © Reuters. FILE PHOTO: Pfizer logo is seen in this illustration taken, May 1, 2022. REUTERS/Dado Ruvic/Illustration 2/2

By Manas Mishra and Michael Erman

(Reuters) - Pfizer Inc (NYSE:PFE) said on Tuesday it will pay $11.6 billion to buy Biohaven Pharmaceutical Holding Co (NYSE:BHVN), making a big bet on its ability to boost sales of the top-selling pill in a new class of migraine drugs.

The boards of both companies have approved the deal, they said. Biohaven shares jumped 70% to $141.31, while Pfizer was up slightly at $48.83.

Pfizer is flush with cash from a once-in-a-lifetime surge in revenue from COVID-19 vaccines and therapeutics and has said it is looking to buy companies or drugs that could add at least $25 billion in annual sales by the end of the decade.

The New York-based drugmaker said Biohaven's migraine drugs could top $6 billion in annual sales at their peak.

The primary asset Pfizer gains from the acquisition is Biohaven's already approved Nurtec ODT, which belongs to a class of migraine treatments called calcitonin gene-related peptide (CGRP) inhibitors. The company also has six other migraine drugs in development.

Nurtec, which brought in sales of $462.5 million in 2021, competes with two CGRP inhibitor pills from AbbVie Inc (NYSE:ABBV). The top selling drugs in the class are injected drugs sold by Eli Lilly (NYSE:LLY) and Co and Amgen Inc (NASDAQ:AMGN).

"The CGRP oral medications, though still somewhat newer entrants in a deeply entrenched space, continue to make steady inroads in disrupting the broader migraine market in the U.S.," said BioHaven Chief Executive Vlad Coric.

Biohaven forecast Nurtec sales of $825 million to $900 million in 2022.

Pfizer said it expects the pills to eventually overtake the shots.

The deal adds a "breakthrough migraine franchise into our portfolio, which we can then enhance and bring to even more patients with our commercial capabilities," Pfizer Chief Business Innovation Office Aamir Malik said on a conference call.

Pfizer said it will double the size of Nurtec's sales force, which will allow it to call on 70,000 additional doctors in the United States. It projected that CGRP inhibitor pills will eventually represent around 40% of prescriptions for migraine drugs, up from around 5% currently.

Under terms of the deal, Pfizer will acquire all Biohaven shares it does not already own for $148.50 per share in cash, a 78.6% premium to Monday's closing price. It took a 2.6% stake in Biohaven in November.

Pfizer plans to spin off Biohaven's non-migraine drugs into a new publicly traded company, it said. Biohaven shareholders will receive 0.5 shares of the new company for each share of Biohaven stock they currently own.

Along with much of the biotech sector, Biohaven's shares had fallen sharply in recent months, losing 45% of their value since they hit $151.26 in October.

"One weight on the sector has been a relative lack of M&A of late, and ... we think this news may be just what the doctor ordered to restore sentiment," said Piper Sandler analyst Christopher Raymond.

The Biohaven deal is Pfizer's largest since its $14 billion purchase of cancer drugmaker Medivation in 2016.

"Investors will like this deal," Wells Fargo (NYSE:WFC) analyst Mohit Bansal said in a note. "Given Pfizer's strong balance sheet, this is still a small acquisition and we would expect more such deals."

Graphic - Pfizer's 5 largest deals in the last six years:

Pfizer to pay $11.6 billion for Biohaven to tap migraine market

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (1)
James Johannsen
James Johannsen May 10, 2022 2:05PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
need migraine medicine for the blood clot shots
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
Sign up with Email